Community Action Needed: Please respond to the NIH RFI
ZFIN ID: ZDB-FIG-190723-253
Iwasaki et al., 2019 - Essential role of prostaglandin E2 and the EP3 receptor in lymphatic vessel development during zebrafish embryogenesis. Scientific Reports   9:7650 Full text @ Sci. Rep.
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Gene:
Fish:
Conditions:
Knockdown Reagents:
Anatomical Term:
Stage: Long-pec
PHENOTYPE:
Fish:
Conditions:
Knockdown Reagents:
Observed In:
Stage: Long-pec

Figure 1

Role of the PGE2-EP3 pathway in lymphatic vessel formation. (A) Tg(fli1a:egfp) embryos were injected with Cont MO, EP3 MO1, or MO2. Images of the trunks were taken at 52 hpf. (B) The ratio of PL-positive segments in nine consecutive segments of (A) was quantitated. Each value represents the mean ± SEM (N = 3–4). (C) Tg(fli1a:egfp) embryos were treated with vehicle (Veh) or indomethacin (Indo; 100 μM) in the absence or presence of sulprostone (Sulp; 1 μM) from 0 to 52 hpf. Images were taken at 52 hpf. (D) The ratio of PL-positive segments in nine consecutive segments of (C) was quantitated. Each value represents the mean ± SEM (N = 3). (E) Tg(fli1a:egfp) embryos were injected with Cont MO, EP3 MO1, or EP3 MO2. Images of the trunks were taken at 5 dpf. (F) The ratio of TD-positive segments in eight consecutive segments of Cont MO- or EP3 MO1-injected morphants was quantitated. Each value represents the mean ± SEM (N = 5–9). **P < 0.01 vs Cont MO. DA: dorsal aorta; ISV: intersomitic vessel; PL: parachordal lymphangioblast; TD: thoracic duct. The PL is indicated by arrowheads, and the TD is indicated by arrows. The number at the bottom right of each panel indicates the number of embryos demonstrating the phenotype shown in the panel over the total number of embryos analyzed in a representative experiment.

Gene Expression Details
Gene Antibody Fish Conditions Stage Anatomy Assay
EGFP y1Tg chemical treatment: indometacin Long-pec vascular lymphangioblast IFL
y1Tg chemical treatment: indometacin, chemical treatment: sulprostone Long-pec vascular lymphangioblast IFL
y1Tg + MO1-ptger3 standard conditions Long-pec vascular lymphangioblast IFL
y1Tg + MO2-ptger3 standard conditions Long-pec vascular lymphangioblast IFL
Antibody Labeling Details No data available
Phenotype Details
Fish Conditions Stage Phenotype
y1Tg chemical treatment: indometacin Long-pec lymphangiogenesis disrupted, abnormal
Long-pec vascular lymphangioblast aplastic/hypoplastic, abnormal
Long-pec vascular lymphangioblast EGFP expression decreased distribution, abnormal
Long-pec vascular lymphangioblast EGFP expression spatial pattern, abnormal
y1Tg chemical treatment: indometacin, chemical treatment: sulprostone Long-pec lymphangiogenesis disrupted, ameliorated
Long-pec vascular lymphangioblast aplastic/hypoplastic, ameliorated
Long-pec vascular lymphangioblast EGFP expression spatial pattern, ameliorated
y1Tg + MO1-ptger3 standard conditions Long-pec lymphangiogenesis disrupted, abnormal
Long-pec thoracic duct aplastic/hypoplastic, abnormal
Long-pec vascular lymphangioblast aplastic/hypoplastic, abnormal
Long-pec vascular lymphangioblast EGFP expression decreased distribution, abnormal
Long-pec vascular lymphangioblast EGFP expression spatial pattern, abnormal
y1Tg + MO2-ptger3 standard conditions Long-pec lymphangiogenesis disrupted, abnormal
Long-pec thoracic duct aplastic/hypoplastic, abnormal
Long-pec vascular lymphangioblast aplastic/hypoplastic, abnormal
Long-pec vascular lymphangioblast EGFP expression decreased distribution, abnormal
Long-pec vascular lymphangioblast EGFP expression spatial pattern, abnormal
Acknowledgments:
ZFIN wishes to thank the journal Scientific Reports for permission to reproduce figures from this article. Please note that this material may be protected by copyright. Full text @ Sci. Rep.